Related Experiment Video
Updated: May 22, 2026

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers
Published on: January 22, 2013
Serum amyloid A: a biomarker for renal cancer
Kersten Fischer1, Gerit Theil, Raschid Hoda
1Department of Urology and Transplant Center of the Martin Luther University Halle-Wittenberg, Halle/Saale, Germany. kersten.fischer@medizin.uni-halle.de
Background/Aim:
Serum amyloid A (SAA) has been identified as a potential biomarker for renal cell carcinoma. We examined its diagnostic value in patients of different tumor stages.
Patients And Methods:
In our study, 48 patients with localized and 67 patients with advanced renal tumors were included. 24 patients served as a control group. Interleukine 6 (IL-6), C-reactive protein (CRP) and SAA levels were measured preoperatively and at day 5 after nephrectomy.
Results:
The IL-6, CRP and SAA levels in patients with advanced tumors are significantly higher than those of patients with localized tumors. Advanced tumors were identified with a sensitivity of 78% (SAA), 69% (CRP) and 44% (IL-6). The specificity was 82%, 82% and 94% for SAA, CRP and IL-6, respectively.
Conclusion:
Our results indicate that advanced renal cancers are accompanied by increased levels of acute-phase proteins such as CRP and SAA. SAA is found to be more sensitive than CRP for the indication of advanced renal cancer.
Related Concept Videos
Serum Studies: Renal Function Tests
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Diabetic Nephropathy
Nephrotic Syndrome II : Assessment and Medical Management
